Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
April 17, 2019 09:05 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc
March 12, 2019 09:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., March 12, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer
November 26, 2018 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc Reports Third Quarter 2018 Results
November 07, 2018 16:15 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada
October 30, 2018 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage
October 02, 2018 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Announces GrafixPL PRIME™ Launches October 1, 2018
September 17, 2018 17:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial
August 27, 2018 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
August 01, 2018 08:00 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...
Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers
July 11, 2018 16:30 ET
|
Osiris Therapeutics, Inc.
COLUMBIA, Md., July 11, 2018 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (OTC Pink:OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics,...